Director/PDMR Shareholding

Bioventix plc

(“Bioventix” or the “Company”)

Director/PDMR Shareholding

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for application in clinical diagnostics, was notified on 19 October 2017 of the following transactions in its ordinary shares of 5 pence each (“Ordinary Shares”):

Director	Position	Ordinary Shares sold	Sale price per Ordinary Share	Ordinary Shares held subsequently	Percentage of issued share capital held subsequently
Ian Nicholson and Persons Closely Associated	Non-Executive Chairman	5,000	2400.75p	18,000	0.4%
Peter Harrison and Persons Closely Associated	CEO	80,000	2425.00p	428,176	8.3%

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

	Details of the person discharging managerial responsibilities / person closely associated
a)	Names	Ian Nicholson (Non-Executive Chairman) Catherine Nicholson (PCA with Ian Nicholson) Peter Harrison (CEO)
	Reason for the Notification
a)	Position/status	See 1(a) above, all are PDMR’s or PCA’s of PDMR’s
b)	Initial notification/Amendment	Initial notification
	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Bioventix plc
b)	LEI	213800225MHX7LZQY108
	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the Financial instrument, type of instrument	Ordinary shares of 5 pence (“Ordinary Shares”)
	Identification code	GB00B4QVDF07
b)	Nature of the transaction	In each case, sale of Ordinary Shares
c)	Price(s) and volume(s)	Ian Nicholson: Price(s) Volume(s) 2400.75p 2,500 Catherine Nicholson: Price(s) Volume(s) 2400.75p 2,500 Peter Harrison: Price(s) Volume(s) 2425.00p 80,000
d)	Aggregated information:	See 4(c)
e)	Date of the transaction	19 October 2017
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

For further information please contact:

Bioventix plc Peter Harrison	Chief Executive Officer	Tel: [phone]
finnCap Ltd Geoff Nash/Simon Hicks Stephen Norcross	Corporate Finance Corporate Broking	Tel: [phone]

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.